View in EDS

EE213 Cost-Effectiveness Analysis of Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer.

Saved in:

Bibliographic Details
Title:	EE213 Cost-Effectiveness Analysis of Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer.
Authors:	Mudumba, R¹ (AUTHOR), Chan, H² (AUTHOR), Cheng, YY² (AUTHOR), Wang, CC² (AUTHOR), Correia, L² (AUTHOR), Ballreich, J² (AUTHOR), Levy, J³ (AUTHOR)
Source:	Value in Health. 2022 Suppl, Vol. 25 Issue 12, pS95-S95. 1p.
Database:	Academic Search Ultimate

Description
ISSN:	10983015
DOI:	10.1016/j.jval.2022.09.462